跳到正文
原文
Medical Xpress·· 2 天前精选AI 评分75

FDA 批准新药用于治疗复发或转移性头颈部鳞状细胞癌

FDA approves new drug for advanced head and neck squamous cell carcinoma

AI 导读

FDA 批准 Janssen Biotech 的 Rybrevant Faspro 用于治疗复发或转移性头颈部鳞状细胞癌,整体响应率为 42%,比现有疗法高。

推荐理由

FDA 批准新药用于治疗复发或转移性头颈部鳞状细胞癌,提升治疗效果。

正文
doctor examine neck
Credit: SHVETS production from Pexels

The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.

Rybrevant Faspro received accelerated approval, the first approval in 10 years of a drug for recurrent or metastatic HNSCC in patients with prior receipt of platinum-based chemotherapy. It is not indicated for treatment of oropharyngeal squamous cell carcinoma associated with human papillomavirus.

The approval is based on a trial of 102 patients with recurrent or metastatic HNSCC. Rybrevant Faspro had an overall response rate of 42% compared with 20% for currently approved therapies. Among patients who had a response to Rybrevant Faspro, 56% had a response lasting six months or longer.

"Today's approval represents a meaningful step forward for patients with HNSCC, a disease where treatment options have historically been limited and outcomes remain poor," Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, said in a statement.

More information

FDA News Release

Clinical categories

Oncology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Copyright © 2026 HealthDay. All rights reserved.

Citation: FDA approves new drug for advanced head and neck squamous cell carcinoma (2026, November 17) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com